Above-Label Doses of Octreotide-LAR in Patients With Metastatic Small Intestinal Carcinoid Tumors

BACKGROUND: Octreotide LAR is indicated for treatment of malignant carcinoid syndrome and has been studied at doses of 10 to 30 mg intramuscularly every 4 weeks. In clinical practice, higher doses are often prescribed for patients who experience refractory carcinoid syndrome (flushing and/or diarrhe...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Strosberg, Jonathan, Weber, Jill, Feldman, Max, Goldman, Jamie, Almhanna, Khaldoun, Kvols, Larry
Format: Artigo
Sprache:Inglês
Veröffentlicht: International Society of Gastrointestinal Oncology 2013
Schlagworte:
Original Research
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3737510/
https://ncbi.nlm.nih.gov/pubmed/23936548
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge